|
| Human FcRH5/FcRL5 Protein (LTP10003) |
|
| LTP10003 |
|
| 100ug |
|
|
$609 In stock |
| FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent. |
| Recombinant Human FcRH5/FcRL5 Protein is expressed from Expi293 with His tag at the C-terminal. It contains Gln16-Gly851. |
|
| FcRH5/FcRL5 |
|
| Human |
|
| AAK93971 |
|
| Gln16-Gly851 |
|
| The protein has a predicted MW of 92.38 kDa. Due to glycosylation, the protein migrates to 120-140 kDa based on the Tris-Bis PAGE result. |
|
| Immobilized Human FcRH5, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-FcRH5 Antibody, hFc Tag with the EC50 of 12.3ng/ml determined by ELISA. See testing image for detail. |
|
| C-His |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
